Show simple item record

dc.contributor.authorKarakas, Zeynep
dc.contributor.authorSayitoğlu, Müge
dc.contributor.authorGelen, Sema Aylan
dc.contributor.authorErbilgin, Yücel
dc.contributor.authorKaraman, Serap
dc.contributor.authorSudutan, Tugce
dc.contributor.authorHatirnaz Ng, Ozden
dc.contributor.authorKucukcankurt, Fulya
dc.contributor.authorCelkan, Tiraje
dc.contributor.authorTimur, Cetin
dc.contributor.authorOzdemir, Gul Nihal
dc.contributor.authorHacısalihoglu, Sadan
dc.date.accessioned2023-02-21T10:12:22Z
dc.date.available2023-02-21T10:12:22Z
dc.date.issued2022
dc.identifier.citationSudutan T., Erbilgin Y., Hatirnaz Ng O., Karaman S., Karakas Z., Kucukcankurt F., Celkan T., Timur C., Ozdemir G. N., Hacısalihoglu S., et al., "Zinc finger protein 384 (<i>ZNF384</i>) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.", Leukemia & lymphoma, cilt.63, sa.12, ss.2931-2939, 2022
dc.identifier.issn1042-8194
dc.identifier.othervv_1032021
dc.identifier.otherav_3f0d984a-a06b-4d57-9b5b-f67e55f63482
dc.identifier.urihttp://hdl.handle.net/20.500.12627/188206
dc.identifier.urihttps://avesis.istanbul.edu.tr/api/publication/3f0d984a-a06b-4d57-9b5b-f67e55f63482/file
dc.identifier.urihttps://doi.org/10.1080/10428194.2022.2095630
dc.description.abstractB-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions. Patients withZNF384rearrangements had a distinct expres- sion profile regardless of their diagnosis, BCP-ALL or mixed phenotype acute leukemia (MPAL) and defined as a new subtype of ALL. In this study, we screened 42 MPAL and 91 BCP-ALL patients for the most commonZNF384fusions; ZNF384::TCF3, ZNF384::EP300andZNF384::TAF15by using PCR. We identifiedZNF384fusions in 9.5% of MPAL and 7.6% of BCP-ALL. A novel breakpoint was identified inZNF384::TCF3fusion in one BCP-ALL patient. T-myeloid MPAL patients showed significantly lowerZNF384expression compared to lymphoid groups. Patients withZNF384r had intermediate survival rates based on other subtypes. Prognostic and patient- specific treatment evaluation ofZNF384fusions in both ALL and MPAL might help to improve risk characterization of patients.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.titleZinc finger protein 384 (<i>ZNF384</i>) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia.
dc.typeMakale
dc.relation.journalLeukemia & lymphoma
dc.contributor.department, ,
dc.identifier.volume63
dc.identifier.issue12
dc.identifier.startpage2931
dc.identifier.endpage2939
dc.contributor.firstauthorID3441843


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record